达巴万星在早期出院和非住院治疗中的作用。是时候把心扔到障碍物上了吗?

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES Global & Regional Health Technology Assessment Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI:10.33393/grhta.2024.3071
Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso
{"title":"达巴万星在早期出院和非住院治疗中的作用。是时候把心扔到障碍物上了吗?","authors":"Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso","doi":"10.33393/grhta.2024.3071","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dalbavancin is a semisynthetic lipoglycopeptide long-acting antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Its features can be useful in the current healthcare scenario characterized by the shortage of available hospital beds.</p><p><strong>Materials methods and results: </strong>We implemented several actions in order to optimize the use of dalbavancin allowing an improvement strategy both from the healthcare system and the patient's perspective in two hospital settings. In the Emergency Department we hospitalized only patients who met the clinical criteria and not the logistic criteria (i.e., the need for antibiotic therapy infusion). During the years 2017-2023, this strategy was applied in 40 cases, thus avoiding 40 hospitalizations for a total saving of 280 days of hospitalization.In the Internal Medicine ward and surgery department when there was no longer any need for hospitalization, we discharged the patient as early as possible. During the years 2017-2023, this strategy was applied in 189 cases, saving at least 1,134 days of hospitalization. The outcome of the treated patients was favorable in 228 out of 229 patients (99.5%).</p><p><strong>Conclusions: </strong>Our experience using dalbavancin in ABSSSI has been very satisfactory overall. The efficacy was close to 100%. Minor adverse events of slight severity occurred rarely. At the same time, this strategy allowed a more efficient allocation of hospital beds. Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292616/pdf/","citationCount":"0","resultStr":"{\"title\":\"Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle?\",\"authors\":\"Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso\",\"doi\":\"10.33393/grhta.2024.3071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dalbavancin is a semisynthetic lipoglycopeptide long-acting antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Its features can be useful in the current healthcare scenario characterized by the shortage of available hospital beds.</p><p><strong>Materials methods and results: </strong>We implemented several actions in order to optimize the use of dalbavancin allowing an improvement strategy both from the healthcare system and the patient's perspective in two hospital settings. In the Emergency Department we hospitalized only patients who met the clinical criteria and not the logistic criteria (i.e., the need for antibiotic therapy infusion). During the years 2017-2023, this strategy was applied in 40 cases, thus avoiding 40 hospitalizations for a total saving of 280 days of hospitalization.In the Internal Medicine ward and surgery department when there was no longer any need for hospitalization, we discharged the patient as early as possible. During the years 2017-2023, this strategy was applied in 189 cases, saving at least 1,134 days of hospitalization. The outcome of the treated patients was favorable in 228 out of 229 patients (99.5%).</p><p><strong>Conclusions: </strong>Our experience using dalbavancin in ABSSSI has been very satisfactory overall. The efficacy was close to 100%. Minor adverse events of slight severity occurred rarely. At the same time, this strategy allowed a more efficient allocation of hospital beds. Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical.</p>\",\"PeriodicalId\":12627,\"journal\":{\"name\":\"Global & Regional Health Technology Assessment\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292616/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global & Regional Health Technology Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33393/grhta.2024.3071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2024.3071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

简介达尔巴万星(Dalbavancin)是一种半合成脂甘肽类长效抗生素,已被批准用于治疗急性细菌性皮肤和皮肤结构感染(ABSSSIs)。在当前病床短缺的医疗环境下,它的特点非常有用:我们采取了多项措施来优化达巴万星的使用,以便从医疗系统和患者的角度出发,在两家医院实施改进策略。在急诊科,我们只让符合临床标准而非逻辑标准(即需要输注抗生素治疗)的患者住院。在 2017-2023 年间,这一策略应用于 40 个病例,从而避免了 40 次住院,共节省 280 天住院时间。在内科病房和外科病房,当不再需要住院治疗时,我们会让患者尽早出院。2017-2023年间,这一策略共应用于189例患者,至少节省了1134天的住院时间。在 229 例患者中,228 例(99.5%)的治疗结果良好:我们使用达巴万星治疗 ABSSSI 的经验总体上非常令人满意。疗效接近 100%。极少发生轻微不良反应。同时,这种策略还能更有效地分配病床。达尔巴万星具有理想的药效学/药代动力学特征,可用于治疗 ABSSSI,尤其是在医院床位紧缺的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle?

Introduction: Dalbavancin is a semisynthetic lipoglycopeptide long-acting antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Its features can be useful in the current healthcare scenario characterized by the shortage of available hospital beds.

Materials methods and results: We implemented several actions in order to optimize the use of dalbavancin allowing an improvement strategy both from the healthcare system and the patient's perspective in two hospital settings. In the Emergency Department we hospitalized only patients who met the clinical criteria and not the logistic criteria (i.e., the need for antibiotic therapy infusion). During the years 2017-2023, this strategy was applied in 40 cases, thus avoiding 40 hospitalizations for a total saving of 280 days of hospitalization.In the Internal Medicine ward and surgery department when there was no longer any need for hospitalization, we discharged the patient as early as possible. During the years 2017-2023, this strategy was applied in 189 cases, saving at least 1,134 days of hospitalization. The outcome of the treated patients was favorable in 228 out of 229 patients (99.5%).

Conclusions: Our experience using dalbavancin in ABSSSI has been very satisfactory overall. The efficacy was close to 100%. Minor adverse events of slight severity occurred rarely. At the same time, this strategy allowed a more efficient allocation of hospital beds. Dalbavancin presents an ideal pharmacodynamic/pharmacokinetic profile for the management of ABSSSI especially in settings where shortage of hospital beds is critical.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Global & Regional Health Technology Assessment
Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-
CiteScore
0.80
自引率
20.00%
发文量
27
审稿时长
8 weeks
期刊介绍: Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.
期刊最新文献
Il burden economico e sociale della porpora trombotica trombocitopenica congenita (cTTP) in Italia. Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study. Analisi di impatto sul budget sanitario italiano di roxadustat per il trattamento dell’anemia da malattia renale cronica. Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview. The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1